SCHEMBL6079947

SCHEMBL6079947

COC(=O)c1cc(-c2ccccc2)c2cccc(OC)c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 3/20 0.55
PDE10A Q9Y233 1/20 0.55
TNKS O95271 1/20 0.51
TNKS2 Q9H2K2 1/20 0.51
PARP2 Q9UGN5 1/20 0.51
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GRM2 Q14416 2/20 0.44
ALOX15 P16050 1/20 0.44
DHODH Q02127 2/20 0.44
FGFR1 P11362 1/20 0.43
SRC P12931 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR4 P22455 1/20 0.43
FGFR3 P22607 1/20 0.43
MMP2 P08253 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1811192 0.90 PDE10A (0.61) ACACAPDE10ATNKSTNKS2PARP2
SCHEMBL6080970 0.89 TNKS (0.54) ACACAPDE10ATNKSTNKS2PARP2
SCHEMBL28879004 0.87 ACACA (0.55) ACACAPDE10ATNKSTNKS2PARP2
SCHEMBL6079384 0.85 ALDH1A1 (0.47) ACACAKDM4EALDH1A1GRM2MMP2
SCHEMBL6081341 0.84 PDE10A (0.47) PDE10ATNKSTNKS2PARP2KDM4E
SCHEMBL1811362 0.84 ALOX15 (0.50) PDE10ATNKSTNKS2PARP2KDM4E
SCHEMBL6080899 0.83 PTGER4 (0.44) ACACAPDE10ATNKSTNKS2PARP2
SCHEMBL561666 0.81 PDE10A (0.47) PDE10ATNKSTNKS2PARP2KDM4E
SCHEMBL13188224 0.81 GRM2 (0.55) ACACATNKSKDM4EALDH1A1GRM2
SCHEMBL6080149 0.81 APP (0.48) KDM4EALDH1A1GRM2MMP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL ACACA 2238/4885PDE10A 702/4885TNKS 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.